Imaging Omics Behavior
|
|
|
- Brian Day
- 5 years ago
- Views:
Transcription
1 Scientific Bases of Health Subclinical Systemic Disease Imaging Omics Behavior ACC New York, Dec 8, 2017 No Disclosures
2 From Aging / Disease to Youth / Health Primordial yrs NHLBI $-1 Primary yrs Secondary yrs Surgery Intervention Pharmacology. Imaging Genetics/Tr 6) SHE 7) HARLEM VILLAGE MEXICO 4) HRP PESA AWHS 5) IIIP 50/50 1) 2) TANSNIP 3) AGING )
3 From Aging / Disease to Youth / Health Primordial yrs NHLBI $-1 Primary yrs Secondary yrs Surgery Intervention Pharmacology. Imaging Genetics/Tr 6) SHE 7) HARLEM VILLAGE MEXICO 4) HRP PESA AWHS 5) IIIP 50/50 1) 2) TANSNIP 3) AGING )
4 Subclinical Atherosclerotic Burden N= 12,000 Carotid 2D/3D-VUS Coronary Calcification B López-Melgar, V Fuster et. al. Atheroscl. 2016;248:230 Validated 3D vs 2D/3D B López-Melgar, V Fuster et. al. J Am Coll Cardiol 2017 (In Press)
5 4a). Subclinical Atherosclerotic Burden Bioimage HRP - N = 5,808 The High Risk Plaque (HRP) or BioImage Studym- Events H Sillesen, P Muntendam, E Falk, V Fuster et.al JACC Imag. 2012;7:681.
6 4a1). The Bioimage Study (N=5808) Cumulative 3-Year MACE Endpoints (N=216) Reclassification: CAC 24% - cpb 18% U Baber, R Mehran, V Fuster, et al. J. Am. Coll. Card. 2015; 65: 1065 Sept 1, Year Follow-up
7 4a2). Modifiable CV RFrs (7) & Life Style AV Khera, V Fuster, PM Ridker et al., NEJM 2016; 375:2349 c c
8 Genetic (50) vs Lifestyle Risk (7) - 55,685 ARIC, MDCS, BioImage, WGHS, AV Khera, V Fuster et.al.nejm 2016;375:2349 >Gen<RF=50% MACE DJ Liu, V Fuster, et al. Nat Genetics 2017 (Press) Lipids S Siddhartha, V Fuster, et.al.nejm 2017;377:111 TET2 / M1
9 CAC Score in the BioImage Study, According to Lifestyle and Genetic Risk AV Khera, V Fuster et. al. N Engl J Med 2016;375:2349
10 Genetic (50) vs Lifestyle Risk (7) - 55,685 ARIC, MDCS, BioImage, WGHS, AV Khera, V Fuster et.al.nejm 2016;375:2349 >Gen<RF=50% MACE DJ Liu, V Fuster, et al. Nat Genetics 2017 (Press) Lipids S Siddhartha, V Fuster, et.al.nejm 2017;377:111 TET2 / M1
11 Loss of Tet2 in Hematopoietic Cells and Atherosclerosis in a Murine Model S. Jaiswal, R Mehran, V Fuster et. al. N Engl J Med 2017;377:111
12 Temporal Sequence & Functions of Leukocytes in the CAs M1 M2 TET2 Arbab-Zadeh, V Fuster. J Am Coll Cardiol 2015;65:846 CAD, MI
13 Local and Systemic Inflammation Interleukin-1 in Ischemic CVD M1 M2 M1 M2 CANTOS Arbab-Zadeh, V Fuster. J Am Coll Cardiol 2015;65:846 P Libby et. al. J Am Coll Cardiol 2016;67:1091 (VF Modified)
14 Circ Res 2017 (In Press) Circ Res. 2017;121. In Press
15 Persistent Stem Cell Driven Inflammation In Atherosclerosis M1 CANAKINUMAB M1 (TET2) TR Cimato. Eur Heart J. 2017;38:433
16 Inflammasome Activates IL-1β by Proteolysis to the Mature Form by Caspase-1 P Libby. J Am Coll Cardiol 2017;70:2278 (Modified by VF) CANAKINUMAB (CVD, HIV) ANAKINRA (HFpEF, HFrEF) COLCHICINE (CVD, E) METHOTREXATE (CVD, E)
17 Coronary PET Inflammation Imaging: ACS Culprit vs Bystander Lesions PM Robson, V Fuster, ZA Fayad et al. J. Am. Coll. Card. 2017;10:1103 JM Tarkin, JHR Rudd et. al. J. Am. Coll/ Card. 2017;69:1774 JMTarkin, Dweck M, Fayad ZA et al. Circ Research 2017 (in Press)
18 Increased Bone Marrow, Spleen, and Arterial FDG Uptake After ACS H Emami, ZA Fayad et. al. J Am Coll Cardiol Img 2015;8:121
19 CV Events According To Whether At 3 Month ontreatment hscrp was > or < 2 mg/l CANTOS (P Ridker et. al.) Lancet 2017 (In Press)
20 High Risk Plaque Study Participants Who Underwent Carotid Ultrasound (Chicago, Florida) Addition Data: Coronary Calcium Biomarkers Genomic markers MRI PET-CT 8 yrs 3-D Carotid Plaque Volume Ultrasound CV Risk Assessment Sept 1, 2017 Long Term Follow-up
21 4b). Study PESA - CNIC Santander
22 4b1). The PESA Study (N=4184) 2D/3D VUS Atherosclerosis Assessment (mm 3 ) PESA (L Fernandez-Friera, A Fernandez-Ortiz, V Fuster et.al) Circulation 2015;131:2104
23 4b2). The PESA Study (N=3860) Femoral And Carotid 3D-VUS Plaque Volume B López-Melgar, V Fuster et. al. J Am Coll Cardiol (In Press)
24 4b2). The PESA Study (N=4184) Subclinical Atherosclerosis & Framingham Risk Score L Fernández-Friera, V Fuster et al., Circulation 2015; 131:2104
25 The PESA Study (N=4184) Subclinical Atherosclerosis & 10 yr European Risk Score L Fernández-Friera, V Fuster et al., Circulation 2015; 131:2104
26 4b3). Absence of Risk Factors Relation Between LDL-C and Atherosclerosis L Fernández-Friera et. al. J Am Coll Cardiol 2017;70:2979
27 4b4). Ideal CV Health Fuster-BEWAT Scores (FBS) JM Fernandez-Alvira, V Fuster, S Pocock et al 2017 (In Press)
28 4c). Framingham, When Positive Coronary Artery Calcification Score and Ultrasound are Added Variables included in the prediction model Variables included in the prediction model AWHS - M Lacaustra, V Fuster et al. JACC 2016; 67: 1263
29 From Aging / Disease to Youth / Health Primordial yrs NHLBI $-1 Primary yrs Secondary yrs Surgery Intervention Pharmacology. Imaging Genetics/Tr 6) SHE 7) HARLEM VILLAGE MEXICO 4) HRP PESA AWHS 5) IIIP 50/50 1) 2) TANSNIP 3) AGING )
30 5a). AMPATH Centers In Kenya BP Control / Non MD / High Technology R Vedanthan, V Fuster, NHLBI / Kenya Model ( )
31 5b). The Seven Community Study N= Spain - E. Gomez, V Fuster et al JACC 2016; 67:476 Cardona Integral Fifty-fifty Global Demonstration Project GHP 2013
32 From Aging / Disease to Youth / Health Primordial yrs NHLBI $-1 Primary yrs Secondary yrs Surgery Intervention Pharmacology. Imaging Genetics/Tr 6) SHE 7) HARLEM VILLAGE MEXICO 4) HRP PESA AWHS 5) IIIP 50/50 1) 2) TANSNIP 3) AGING )
33 2). Risk Factors of CV Disease White Matter & Lacunar Lesions (DBD) MA Lim et. al. Clin Geriatr Med. 2009;25:191. JC Kovacic, V Fuster et. al. Circulation. 2011;123:1900
34 Microcirculation, Cognitive 12 Studies 1.V Novak, I Hajjar. Nat. Rev. Cardiol. 2010; 7:686 A sd 2.HW Querfurth et al NEJM 2010;362:329 Isch % A sd 3.JC Kovacic, V Fuster et. al. Circ. 2011;123:1900-MacVD/LL 4. CARDIA (K Yaffe et al) Circ 2014;129: CV RFrs, Cognitive 5.JI Friedman et al. JACC CV Imag. 2014;7: Imaging 6. JT O Brien et. al. Lancet. 2015;386: Autopsy 7. FINGER (T Ngandu et al)., Lancet 2015; 385: Intervention
35 Microcirculation, Cognitive 12 Studies.P Scheltens et al Lancet 2016;388:507 RF<Dementia 30%.C Iadecola et al., Hypert. 2016;68:e67- Hypert. Alzheimer s 0. A de Roos et. al. Circ. 2017; 135: Aging<Pulse/Perf 1.YFS (SP Rovio et al), JACC 2017(In Press)-RF Child. Cogn. 2.TANSNIP Paths 1 & 2 (V Fuster et al) A Prospective
36 11. Cardiovascular Risk Factors From Childhood & Midlife Cognitive Performance YFS (SP Rovio et al), J Am Coll Card 2017 (In Press)
37 12a.TANSNIP Pathway 1 STEP 1: Neurocognitive battery Cognitive impaired N=50 Cognitive Normal N=50 CV Risk Assessment CACS 3DVUS-Carotid Plaque Volume and ileo-femoral N=2750 FAD PET for Amyloid MRI- functional + Micro/ Macrovasculature
38 12b. TANSNIP Pathway 2 STEP 1: CACS Carotid Plaque w Volume Continuous Scale N=100 Source- MSH Coronary CT Suites CV Risk Assessment 3-D carotid and ileo-femoral ultrasound PET for Amyloid Neurocognitive Testing MRI- functional + Micro /Macrovasculature
39 From Aging / Disease to Youth / Health Primordial yrs NHLBI $-1 Primary yrs Secondary yrs Surgery Intervention Pharmacology. Imagin Genetics/Tr 6) SHE 7) HARLEM VILLAGE MEXICO 4) HRP PESA AWHS 5) IIIP 50/50 1) 2) TANSNIP 3) AGING )
40 Scientific Bases of Health Subclinical Systemic Disease Imaging Omics Behavior ACC New York, Dec 8, 2017 No Disclosures
The Evolving Science of Health Imaging, Genetics and Behavior. The Heart and the Brain
The Evolving Science of Health Imaging, Genetics and Behavior The Heart and the Brain Lima, Nov 17, 2018 No Disclosures From Aging / Disease to Youth / Health Primordial 00-25 yrs NHLBI $-1 Primary 25-50
The Three Upcoming Challenges
From Aging/Disease to Youth/Health Economic, Scientific, Educational The Three Upcoming Challenges New York, Dec 9, 2016 No Disclosures NHLBI Strategic Agenda - 2025 M Lauer, GH Gibbons et. al. JACC 2015;
Leadership & Motivation
PROMOTING HEALTH CHILDREN, FAMILY & COMMUNITY Leadership & Motivation ACC-New York, Dec. 11, 2015 No Disclosures Documents on Global CV Health Follow-up? Promoting Cardiovascular Health in the Developing
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
The PESA-CNIC-Santander Study (Progression of Early Subclinical Atherosclerosis)
XXXIV LECCIÓN MEMORIAL Fundación Fernández-Cruz Today Moving Frontiers to Stay Healthy and Living Well Forever The PESA-CNIC-Santander Study (Progression of Early Subclinical Atherosclerosis) Antonio Fernández-Ortiz
Coronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute
Coronary Artery Calcium Vimal Ramjee, MD FACC The Chattanooga Heart Institute Disclosures I have no conflicts of interest to disclose. Objectives Recognize the utility of coronary artery calcium scoring
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
PESA CNIC-SANTANDER STEMI
VF-3D-ESSOS Fuster-CNIC-Ferrer Cardiovascular Polypill and SECURE Trial ATHEROBRAIN H2H Study PESA CNIC-SANTANDER STEMI Trials: The Metoprolol program TAN SNIP VF-3D-ESSOS STUDY MRI is the gold standard
INFLAMMATION &THROMBOSIS INSIGHTS FROM CANTOS TRIAL AHMED NADA, FSCAI ALMOSTAKBAL HOSPITAL, JEDDAH SAUDI ARABIA
INFLAMMATION &THROMBOSIS INSIGHTS FROM CANTOS TRIAL AHMED NADA, FSCAI ALMOSTAKBAL HOSPITAL, JEDDAH SAUDI ARABIA Introduction - Two or three decades ago, many experts predicted that the modification of
CLINICAL STUDIES. PESA CNIC-SANTANDER Fuster-CNIC-Ferrer Cardiovascular Polypill and SECURE Trial STEMI trials: The Metroprolol program TAN SNIP AWHS
PESA CNIC-SANTANDER Fuster-CNIC-Ferrer Cardiovascular Polypill and SECURE Trial STEMI trials: The Metroprolol program TAN SNIP AWHS PESA CNIC-SANTANDER (Progression of Early Subclinical Atherosclerosis)
SCIENCE, HEALTH, EDUCATION. 4 Ts, 4 As
SCIENCE, HEALTH, EDUCATION 4 Ts, 4 As SHE, Community, All Ages The Circle of Leadership Valentín Carulla President Barcelona University (1913-23) SCIENCE, HEALTH, EDUCATION 4 Ts, 4 As 1. UN Targets Top
Current and Future Imaging Trends in Risk Stratification for CAD
Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction
New Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
Diagnostic and Prognostic Value of Coronary Ca Score
Diagnostic and Prognostic Value of Coronary Ca Score Dr. Ghormallah Alzahrani Cardiac imaging division, Adult Cardiology department Prince Sultan Cardiac Center ( PSCC) Madina, June 2 Coronary Calcium
Complex CAD (5) PVD-P Valv. CM. Sub-Clinical Arterial (2) DBD/Frailty (2) Health Political (1) Personal (3)
1. A Transition From Disease to Health 2. Heart Brain Integration 3. Imaging / Omics / Regeneration / Life Style Complex CAD (5) PVD-P Valv. CM AF Sub-Clinical Arterial (2) DBD/Frailty (2) Health Political
Coronary Artery Calcification
Coronary Artery Calcification Julianna M. Czum, MD OBJECTIVES CORONARY ARTERY CALCIFICATION Julianna M. Czum, MD Dartmouth-Hitchcock Medical Center 1. To review the clinical significance of coronary heart
CVD risk estimation in populations with high prevalence of MetS. Dilek Ural, 12 March 2017 Koç University, Istanbul
CVD risk estimation in populations with high prevalence of MetS Dilek Ural, 12 March 2017 Koç University, Istanbul Understanding CV risk Likelihood of a person developing an atherosclerotic CV event over
HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications
HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications Matthew J. Feinstein, MD, MSc Assistant Professor of Medicine Northwestern University Feinberg School of Medicine Chicago,
CVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
Vascular calcification in patients with Diabetes Mellitus. Dr Jamie Bellinge University of Western Australia Royal Perth Hospital
Vascular calcification in patients with Diabetes Mellitus Dr Jamie Bellinge University of Western Australia Royal Perth Hospital Risk of cardiovascular disease Cardiovascular disease; - Stroke - Coronary
MEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
Molecular Imaging of Coronary Plaques
Molecular Imaging of Coronary Plaques Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute CSMC 20113 Professor of Medicine David Geffen School of Medicine at UCLA Zahi A. Fayad,
How to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
Better CABGs vs Better PCI Devices
CABG vs PCI 2017 Multivessel Coronary Disease Better CABGs vs Better PCI Devices ACC New York, Dec 8, 2017 No Disclosures CABG vs PCI 2017 Stable Multivessel Coronary Disease 1. Are These The two Critical
JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
Multi-Modality Imaging of Atherosclerosis in HIV Ahmed Tawakol, MD
Multi-Modality Imaging of Atherosclerosis in HIV Ahmed Tawakol, MD Director, Integrative Bio-Imaging Trials Program Co-Director Cardiac MR PET CT Program Massachusetts General Hospital Harvard Medical
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
Cottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?
Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,
Atherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials
Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials ESC Munich August 25, 2012 Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School
Journal of the American College of Cardiology
1/5 Journal of the American College of Cardiology Volume 70, Issue 15, October 2017 DOI: 10.1016/j.jacc.2017.08.027 PDF Article The Importance of Breakfast in Atherosclerosis Disease Insights From the
The Art of Cardiovascular Risk Assessment
The Art of Cardiovascular Risk Assessment Laurence S. Sperling, M.D., FACC, FACP,FAHA, FASPC Professor of Medicine (Cardiology) Professor of Global Health Director- Center for Heart Disease Prevention
The Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
Who Cares About the Past?
Risk Factors, the New Calcium Score, Rheology and Atherosclerosis Progression Arthur Agatston 2/21/15 The Vulnerable Plaque vs. Plaque Burden CT Angiogram Is There a Role for Coronary Artery Calcium Scoring
Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD
Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Cardiovascular Research Laboratories Research Institute of the McGill University Health Center Disclosure J.
Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
Women and Coronary Artery Disease:
Women and Coronary Artery Disease: Less is More? Interventional Cardiology 2017 32 th Annual International Symposium Snow Mass March 5-10 Yolande Appelman MD, PhD,FESC EAPCI-Women Interventional Cardiologist
Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.
Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management None Disclosures Arthur Agatston Conceptual Approach to CAD Risk Devereux Circulation, 1993 1 Age Obesity Family Hx Diabetes
PCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
Beyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017
Coronary Artery Calcification Dharmendra A. Patel, MD MPH Director, Echocardiography Laboratory Associate Program Director Cardiovascular Disease Fellowship Program Erlanger Heart and Lung Institute UT
Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California
Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
Dyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
Best Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
Assessing atherosclerotic risk for long term preventive treatment
Assessing atherosclerotic risk for long term preventive treatment Donald A. Smith, MD, MPH Endocrinologist, Clinical Lipidologist Associate Professor of Medicine and Preventive Medicine Icahn School of
Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging
Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute Professor of Medicine and Imaging Cedars-Sinai
Sanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
MEDICAL POLICY. 02/15/18 CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease
21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease Noninvasive Evaluation of Coronary Artery Disease: Anatomical, Functional, Clinical May 5, 2018 Mark Hansen MD FRCPC Cardiologist,
Inflammation: Novel Target for Cardiovascular Risk Reduction
Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low
Statin Use and Cardiovascular Disease in HIV
Statin Use and Cardiovascular Disease in HIV Steven K. Grinspoon, MD Professor of Medicine Harvard Medical School Boston, Massachusetts FLOWED: 04/18/16 Los Angeles, California: April 25, 2016 Statin Use
MOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL
MOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL DEFINITION OF A SCREENING TEST TESTING FOR A DISEASE OR CONDITION IN ASYMPTOMATIC PERSONS TO IDENTIFY THE CONDITION BEFORE IT MANIFESTS
surtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
CARDIAC IMAGING FOR SUBCLINICAL CAD
CARDIAC IMAGING FOR SUBCLINICAL CAD WHY DON'T YOU ADOPT MORE SMART TECHNIQUE? Whal Lee, M.D. Seoul National University Hospital Department of Radiology We are talking about Coronary artery Calcium scoring,
Carotid Ddisease, Carotid IMT and Risk of Stroke
Carotid Ddisease, Carotid IMT and Risk of Stroke TATJANA RUNDEK, MD PhD Professor of Neurology, Epidemiology and Public Health Director, Clinical translational Division Department of Neurology, Miller
Weintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
The Vulnerable Plaque- Pharmacological Approaches
The Vulnerable Plaque- Pharmacological Approaches J. C. Kaski, M.D., D.M (Hons.), D.Sc., F.E.S.C., F.R.C.P., F.A.C.C., F.A.H.A. Cardiovascular and Cell Sciences Research Institute DISCLOSURES Speaker honoraria
Depression and Subclinical Vascular Diseases in Psoriasis
Depression and Subclinical Vascular Diseases in Psoriasis Nehal N. Mehta, MD MSCE FAHA Section Chief, Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, USA Lasker Clinical
Learning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III
Presenter Disclosure Information 10:30 11:15am Predicting and Preventing Cardiovascular Disease: Can we put the Cardiologist out of business? The following relationships exist related to this presentation:
Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil
Defining Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD Brazil 1 Disclosure Honoraria received for consulting, speaker and or researcher activities : Astra Zeneca, Akcea, Amgen, Biolab, Esperion,
Imaging in the Evaluation of Coronary Artery Disease and Abdominal Aortic Aneurysm
Imaging in the Evaluation of Coronary Artery Disease and Abdominal Aortic Aneurysm Mark J. Sands, MD Vice Chairman, Imaging Institute Clinical Operations and Quality Objectives Review of available radiologic
1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
Can We Cure Atherosclerosis?
Can We Cure Atherosclerosis? Jennifer G Robinson MD MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University of Iowa What if you had a guide To guarantee
Short and Long Term Prognosis after Coronary Artery Calcium Scoring
Short and Long Term Prognosis after Coronary Artery Calcium Scoring In Pre-Elderly and Elderly Patients Michael J. Blaha MD MPH Presented by: Michael J. Blaha July 24, 2017 1 Talk Outline 1. Coronary artery
Prospective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
CRP for the Clinician
CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University
Optimal testing for coronary artery disease in symptomatic and asymptomatic patients
Optimal testing for coronary artery disease in symptomatic and asymptomatic patients Alexandre C Ferreira, MD Clinical Chief of Cardiology Jackson Health System Director, Interventional Cardiology Training
Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
Advanced Imaging MRI and CTA
Advanced Imaging MRI and CTA Who and why may benefit. Matthew W. Martinez, M.D. FACC Lehigh Valley Health Network Director, Cardiovascular Imaging Learning Objectives Review basics of CMR and CTA Review
Environmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
Physical Activity and Coronary calcification ADJ ASSOCIATE PROFESSOR TAN SWEE YAW NATIONAL HEART CENTRE SINGAPORE
Physical Activity and Coronary calcification ADJ ASSOCIATE PROFESSOR TAN SWEE YAW NATIONAL HEART CENTRE SINGAPORE Calcium Scores (CACS) Calcium Scores (CACS) Calcium Scores are indicative of the presence
2013 Lipid Guidelines Practical Approach. Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS
2013 Lipid Guidelines Practical Approach Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS EVIDENCE BASED MEDICINE Case #1 - LB 42 yo Asian/American female who was
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology
FFR-CT Not Ready for Primetime
FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
Risk Stratification for CAD for the Primary Care Provider
Risk Stratification for CAD for the Primary Care Provider Shimoli Shah MD Assistant Professor of Medicine Directory, Ambulatory Cardiology Clinic Knight Cardiovascular Institute Oregon Health & Sciences
The role of coronary artery calcium score on the detection of subclinical atherosclerosis in metabolic diseases
The role of coronary artery calcium score on the detection of subclinical atherosclerosis in metabolic diseases Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital Sungkyunkwan
Coronary Artery Calcium: Absence Makes the Heart Younger?
Coronary Artery Calcium: Absence Makes the Heart Younger? Parag H. Joshi, MD, MHS, FACC Assistant Professor of Medicine Division of Cardiology University of Texas Southwestern Medical Center Department
Disclosures. May 15 th, Influenza Vaccination as Secondary Prevention for Acute Coronary Events Where do we need to go in clinical practice?
Influenza Vaccination as Secondary Prevention for Acute Coronary Events Where do we need to go in clinical practice? May 15 th, 2014 Robi Goswami, MD Cardiologist Piedmont Heart Institute Disclosures None
American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
INFLAMMATION AND ATHEROSCLEROSIS. Rob Greenfield MD FACC FAHA FNLA California Heart Associates University of California, Irvine
INFLAMMATION AND ATHEROSCLEROSIS Rob Greenfield MD FACC FAHA FNLA California Heart Associates University of California, Irvine What determines who will develop atherosclerosis? LDL-CHOLESTEROL?? OTHER
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
Joshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines
Summary Implementing new Dyslipidemia Guidelines Implementation of CV Risk and Dyslipidemia Guidelines Ronald D. Scott, MD Regional KPSC CVD Co-Lead Family Medicine and Lipidology, WLA ASCVD (Atherosclerotic
USING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK
USING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK JAMES M FALKO MD PROFESSOR OF MEDICINE UNIVERSITY OF COLORADO Adapted from: Rader D. N Engl J Med. 2000 hs-crp (mg/l) 6 5 4 3 2 1 *p
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
Bold Plans to Overcome Health Disparities: Using Imaging, Prevention and Big Data with Tobacco-Related Diseases
Bold Plans to Overcome Health Disparities: Using Imaging, Prevention and Big Data with Tobacco-Related Diseases Tochi M. Okwuosa, DO, FACC Rush University Medical Center Objectives Disparities in Smoking
Modern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
Rikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
Biomarkers in Cardiovascular Diseases. Peter Ganz, MD. Chief, Division of Cardiology, San Francisco General Hospital
Biomarkers in Cardiovascular Diseases Peter Ganz, MD Chief, Division of Cardiology, San Francisco General Hospital Maurice Eliaser Jr. Distinguished Professor of Medicine, University of California, San